Immune Pharmaceuticals Inc (fka IMNPQ)

[Letterpenny]

Shut Up Insider…..

Massimo Radaelli
President & CEO presso Noventia Pharma
3d

Dear Daniel

I fully agree on this new vision adopting the hub-and-spoke model, as a very nnovative strategy involving multiple portfolio companies or subsidiaries under the same umbrella, each addressing a different area of treatment

And last but not least investing in this type of companies could come with less risk because if one area doesn't perfectly work out the way management expects, the other areas could lend the additional support required.

Thus means that addressing multiple technologies or treatment areas enables a company to attract capital from a broader range of investors

I wish the best for. Naya